2 unknown, 1 active not recruiting. 3 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Unknown 2, Active not recruiting 1 |
| Phase 2 | 2 | Active not recruiting 1, Unknown 1 |
Follow seclidemstat: new trials by email Literature Review of seclidemstat trials Research Report on seclidemstat
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Rollover Protocol to Allow for Continued Access to the LSD1 Inhibitor Seclidemstat (SP-2577) Seclidemstat - Ewing Sarcoma, Myxoid Liposarcoma | Phase 1 / Phase 2 | Unknown | Salarius Pharmaceuticals, LLC | 10 | 2022-01-15 | 2023-08-01 |
| Seclidemstat and Azacitidine for the Treatment of Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia Azacitidine, Seclidemstat - Chronic Myelomonocytic Leukemia-0, Chronic Myelomonocytic Leukemia-1 | Phase 1 / Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 24 | 2021-07-07 | 2026-09-18 |
| Clinical Trial of SP-2577 (Seclidemstat) in Patients With Relapsed or Refractory Ewing or Ewing-related Sarcomas Seclidemstat, Cyclophosphamide, Topotecan - Ewing Sarcoma, Myxoid Liposarcoma | Phase 1 | Unknown | Salarius Pharmaceuticals, LLC | 50 | 2018-06-04 | 2023-11-21 |
Chondrosarcoma, Extraskeletal Myxoid (2) · Desmoplastic Small Round Cell Tumor (2) · Histiocytoma, Angiomatoid Fibrous (2) · Liposarcoma, Myxoid (2) · Myoepithelioma (2) · Sarcoma, Clear Cell (2) · Sarcoma, Ewing (2) · Fibroma (1) · Leukemia, Myelomonocytic, Chronic (1) · Myelodysplastic Syndromes (1) · Sarcoma (1)
Salarius Pharmaceuticals, LLC (2) · M.D. Anderson Cancer Center (1)
United States (3)